FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296799460> ?p ?o ?g. }

• W4296799460 abstract "Dear editor, We demonstrated in this study that functional CAR peptide-labelled mitochondria were detectable in venous blood and in lungs of rats after enteric encapsulation and oral administration, and were able to attenuate pulmonary hypertension in two different experimental models. Pulmonary hypertension is characterised by pulmonary vasoconstriction and remodelling, resulting in increased pulmonary vascular resistance eventually leading to right heart failure and death. It is well known that hypoxia induces pulmonary vasoconstriction,1, 2 but causes systemic vessel vasodilation.3, 4 One explication for these discrepancies in terms of hypoxia response may be the function and structure heterogeneity of mitochondria in smooth muscle cells from pulmonary vessels compared to systemic vessels.5, 6 Our recent studies have shown that femoral artery smooth muscle cell-derived mitochondria via intravenous injection can be transplanted into pulmonary artery smooth muscle cells (PASMCs), a process attenuating pulmonary hypertension.5, 6 Mitochondria transplantation for conditions associated with mitochondrial dysfunction is emerging as a novel therapeutic strategy. Previous studies have conducted mitochondrial transplantation mainly by intravenous,5, 6 tissue injection7 and nebulization.8 If mitochondrial transplantation could be performed orally, it would greatly improve its safety and convenience. To address this issue and considering the biological specificity of mitochondria, we linked the CAR peptide, a cyclic peptide with cell-penetrating properties and lung targeting properties,9, 10 to mitochondria via the mitochondrial outer membrane localization peptide. Five mitochondrial outer membrane localization peptides were screened to link CAR peptide to the surface of the mitochondrial outer membrane, and then labelled with FITC (Figure 1A). We found higher labelling efficiency for peptides -1, -3, -5 rather than peptides -2, -4 (Figure 1B). Therefore, the peptides-1, -3, -5 were used in subsequent experiments. To assess whether CAR peptide-labelled mitochondria could be absorbed into the blood through the small intestine, they were encapsulated to prevent any damage caused by acidic gastric secretions and administered to rats by gavage (see supplement). Labelled mitochondria were detectable after 4 h in the blood, 8 h in the lungs and heart (Figure 1C–E), ∼20–24 h with very small amounts in liver, while they were undetectable in brain or kidneys (Figure 1F). We found that the number of labelled mitochondria in erythrocytes was much higher than that in plasma(∼4.64 fold) and white blood cells(∼8.91 fold, Figure 2A), and the number of mitochondria in venous erythrocytes increased significantly after oral administration of mitochondria labelled with peptides -1, -3, -5 compared with the vehicle group (Figure 2B). Furthermore, the number of erythrocytes containing mitochondria was higher in venous blood than in arterial blood, and also higher in unoxygenated venous blood (venous blood control) than in oxygenated venous blood (venous blood oxygenation) (Figure 2C). The same trends were observed in the mitochondria number in erythrocytes (Figure 2C). The number of mitochondria per erythrocyte containing mitochondria was greater in unoxygenated venous erythrocytes than in oxygenated venous erythrocytes, while no significant difference was observed between venous erythrocytes and arterial erythrocytes (Figure 2C). The number of erythrocytes containing mitochondria in venous blood and the total number of mitochondria per 105 venous erythrocytes were also superior at 8 h than at 48 h after gavage (Figure 2C). The transwell experiments on the erythrocytes charged with CAR-labelled mitochondria highlighted an increased mitochondria release from erythrocytes with increased oxygen partial pressure (Figure 2D). These results suggest that mitochondrial release from erythrocytes may be regulated at least in part by oxygen partial pressure, and the release of mitochondria from erythrocytes may be in an All-or-None process in vivo, while in vitro the mechanism is somewhat between “All-or-None” with “partial” release. CAR peptide-labelled mitochondria were also obtained by immunoprecipitation with FITC antibody and were then functionally analysed for ATP production, respiratory control rate and membrane potential. The combined results showed that exogenous mitochondria absorbed in venous blood and lungs were functional (Figure 2E). To determine the molecular mechanism of the absorption of mitochondria through the intestine, we screened intestinal protein candidates after interaction with exogenous mitochondria. A total of 2127 proteins were identified, and three of them were receptor proteins that have been known to mediate endocytosis or transcytosis, including TGF-beta receptor type-2 (TGFBR2), transferrin receptor protein 1 (TFRC) and low-density lipoprotein receptor-related protein 2 (LRP2). To explore which protein(s) mediates the transcytosis process of CAR-labelled mitochondria, we implemented transwell experiments on the rat intestinal villus epithelial cells with CAR-labelled mitochondria and found that LRP2, but not TFGBR2 or TFRC knockdown using shRNA, significantly reduced the transcytosis of CAR peptide-labelled mitochondria (Figure 2F). In rats under chronic hypoxia exposure or treated with a single intraperitoneal injection of monocrotaline (MCT), peptide-5-labelled mitochondria encapsulated with enteric capsules attenuated pulmonary hypertension as illustrated by the significant decrease of mPAP, PVR， RV/(LV+S) ratio and pulmonary artery wall thickness (Figure 3A–C). This improvement was associated with enhanced mitochondrial function in rat pulmonary arteries (Figure 3D,E). However, the benefits of CAR-labelled mitochondria were lost with LRP2 silencing. Molecular mechanisms underlying the benefits of CAR-labelling mitochondria also involved the reduction of extracellular calcium-sensing receptors expression and related calcium signalling (Figure 4A–C), an important mediator of pulmonary hypertension as revealed in recent studies including ours. To confirm the localization of exogenous mitochondria in pulmonary artery, immunogold electron microscopy was conducted to examine pulmonary artery smooth muscle cells in rats, and gold particles were clearly identified in some PASMCs after intragastric administration of enteric-coated capsules containing peptide 5-labelled mitochondria (Figure 4D). In conclusion, our data demonstrate that CAR peptide-labelled mitochondria are absorbed from the intestine into blood after oral administration. The mechanism of mitochondrial uptake is associated with LRP2-mediated transcytosis. We also showed that exogenous mitochondria absorbed into venous blood were mainly distributed into erythrocytes and were carried into the lungs. The release of mitochondria from erythrocyte was driven at least in part by increased oxygen partial pressure upon blood re-oxygenation in lungs. Oral administration of encapsulated CAR peptide-labelled mitochondria attenuated both hypoxia- and MCT-induced pulmonary hypertension in rats. Our study provides a novel approach for easy and effective treatment of pulmonary hypertension, and reveals a new mechanism underlying exogenous mitochondria transportation and delivery through erythrocytes as carriers. This work was supported by grants from the National Natural Science Foundation of China (82270060, 82130002, 82170068, 31771275, 81770055, 81861128024, 81922001, 81770052, 81800053 and 31800980), and Wuhan Department of Science and Technology (2020020601012233). The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W4296799460 created "2022-09-24" @default.
• W4296799460 creator A5008927356 @default.
• W4296799460 creator A5020497561 @default.
• W4296799460 creator A5022140403 @default.
• W4296799460 creator A5058625550 @default.
• W4296799460 creator A5060267763 @default.
• W4296799460 creator A5065879487 @default.
• W4296799460 creator A5069575202 @default.
• W4296799460 creator A5077361754 @default.
• W4296799460 creator A5078082347 @default.
• W4296799460 creator A5080467834 @default.
• W4296799460 creator A5085352453 @default.
• W4296799460 date "2022-09-01" @default.
• W4296799460 modified "2023-10-15" @default.
• W4296799460 title "Orally‐administrated mitochondria attenuate pulmonary hypertension with the aid of erythrocytes as carriers" @default.
• W4296799460 cites W1988714749 @default.
• W4296799460 cites W2024825549 @default.
• W4296799460 cites W2059189153 @default.
• W4296799460 cites W2121580924 @default.
• W4296799460 cites W2158416935 @default.
• W4296799460 cites W2165555244 @default.
• W4296799460 cites W2338719152 @default.
• W4296799460 cites W2462913190 @default.
• W4296799460 cites W2588176399 @default.
• W4296799460 cites W2740802860 @default.
• W4296799460 cites W2984718425 @default.
• W4296799460 doi "https://doi.org/10.1002/ctm2.1033" @default.
• W4296799460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36149749" @default.
• W4296799460 hasPublicationYear "2022" @default.
• W4296799460 type Work @default.
• W4296799460 citedByCount "2" @default.
• W4296799460 countsByYear W42967994602023 @default.
• W4296799460 crossrefType "journal-article" @default.
• W4296799460 hasAuthorship W4296799460A5008927356 @default.
• W4296799460 hasAuthorship W4296799460A5020497561 @default.
• W4296799460 hasAuthorship W4296799460A5022140403 @default.
• W4296799460 hasAuthorship W4296799460A5058625550 @default.
• W4296799460 hasAuthorship W4296799460A5060267763 @default.
• W4296799460 hasAuthorship W4296799460A5065879487 @default.
• W4296799460 hasAuthorship W4296799460A5069575202 @default.
• W4296799460 hasAuthorship W4296799460A5077361754 @default.
• W4296799460 hasAuthorship W4296799460A5078082347 @default.
• W4296799460 hasAuthorship W4296799460A5080467834 @default.
• W4296799460 hasAuthorship W4296799460A5085352453 @default.
• W4296799460 hasBestOaLocation W42967994601 @default.
• W4296799460 hasConcept C126322002 @default.
• W4296799460 hasConcept C185592680 @default.
• W4296799460 hasConcept C2780930700 @default.
• W4296799460 hasConcept C28859421 @default.
• W4296799460 hasConcept C55493867 @default.
• W4296799460 hasConcept C71924100 @default.
• W4296799460 hasConcept C98274493 @default.
• W4296799460 hasConceptScore W4296799460C126322002 @default.
• W4296799460 hasConceptScore W4296799460C185592680 @default.
• W4296799460 hasConceptScore W4296799460C2780930700 @default.
• W4296799460 hasConceptScore W4296799460C28859421 @default.
• W4296799460 hasConceptScore W4296799460C55493867 @default.
• W4296799460 hasConceptScore W4296799460C71924100 @default.
• W4296799460 hasConceptScore W4296799460C98274493 @default.
• W4296799460 hasFunder F4320321001 @default.
• W4296799460 hasIssue "9" @default.
• W4296799460 hasLocation W42967994601 @default.
• W4296799460 hasLocation W42967994602 @default.
• W4296799460 hasLocation W42967994603 @default.
• W4296799460 hasOpenAccess W4296799460 @default.
• W4296799460 hasPrimaryLocation W42967994601 @default.
• W4296799460 hasRelatedWork W2046069863 @default.
• W4296799460 hasRelatedWork W2048862592 @default.
• W4296799460 hasRelatedWork W2333145688 @default.
• W4296799460 hasRelatedWork W2410314862 @default.
• W4296799460 hasRelatedWork W2412645198 @default.
• W4296799460 hasRelatedWork W2595673966 @default.
• W4296799460 hasRelatedWork W2790232384 @default.
• W4296799460 hasRelatedWork W2990595088 @default.
• W4296799460 hasRelatedWork W2999964781 @default.
• W4296799460 hasRelatedWork W584255262 @default.
• W4296799460 hasVolume "12" @default.
• W4296799460 isParatext "false" @default.
• W4296799460 isRetracted "false" @default.
• W4296799460 workType "article" @default.